Research Paper|Volume 15, Issue 12|pp 5673—5697

DUSP10 is a novel immune-related biomarker connected with survival and cellular proliferation in lower-grade glioma

Feng Xiao^1,^2,^3,⁴, Hong Zhu^1,^2,^3,⁴, Yun Guo^1,^2,^3,⁴, Zhe Zhang^1,^2,^3,⁴, Gufeng Sun^1,^2,^3,⁴, Kai Huang^1,^2,^3,⁴, Hua Guo^1,^2,^3,⁴, Guowen Hu¹

¹Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China
²Jiangxi Key Laboratory of Neurological Tumors and Cerebrovascular Diseases, Nanchang 330006, Jiangxi, China
³Jiangxi Health Commission Key Laboratory of Neurological Medicine, Nanchang 330006, Jiangxi, China
⁴Institute of Neuroscience, Nanchang University, Nanchang 330006, Jiangxi, China

Received: February 7, 2023Accepted: June 6, 2023Published: June 29, 2023

https://doi.org/10.18632/aging.204821

Copyright: © 2023 Xiao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Objective: The role of dual-specificity phosphatase 10 (DUSP10) has been investigated in several types of cancer. Nevertheless, the underlying function of DUSP10 in lower-grade glioma (LGG) remains undetermined.

Methods: We entirely determined the expression features and prognostic significance of DUSP10 in numerous tumors by implementing a pan-cancer analysis. Adjacently, we thoroughly inspected the correlation between DUSP10 expression and clinicopathologic features, prognosis, biological processes, immune traits, gene variations, and treatment responses based on the expression features in LGG. In vitro studies were conducted to detect the underlying functions of DUSP10 in LGG.

Results: Unconventionally boosted DUSP10 expression and higher DUSP10 expression correlated with poorer prognosis were discovered in various tumors, including LGG. Fortunately, DUSP10 expression was proven to be an independent prognostic indicator of patients with LGG. Additionally, DUSP10 expression was tightly linked to the immune modulation, gene mutations, and response to immunotherapy/chemotherapy in LGG patients. In vitro studies illustrated that the DUSP10 was abnormally increased and pivotal for cell proliferation in LGG.

Conclusions: Collectively, we verified that DUSP10 was an independent prognostic indicator and may become a novelty target of targeted therapy of LGG.